about
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumorRandomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccineImmunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines.Other targetable sarcomas.Bone cancer.Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor.Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor.A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumorsA phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumorsDoxorubicin resistance in a novel in vitro model of human pleomorphic liposarcoma associated with alternative lengthening of telomeres.Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.Peripheral primitive neuroectodermal tumor of the dura in a 51-year-old woman following intensive treatment for breast cancerNCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors.Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor.The role of adjuvant and neoadjuvant therapy in gastrointestinal stromal tumors.Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors.Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines.Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.Soft tissue sarcoma, version 2.2014.Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.Monoclonal antibody therapy for cancer.Pharmacotherapy of gastrointestinal stromal tumours.Gastrointestinal stromal tumors: a paradigm for molecularly targeted therapy.New therapeutic strategies for soft tissue sarcomas.Towards global consensus in the treatment of gastrointestinal stromal tumorColorectal cancer vaccines: what we know and what we don't yet know.New drugs and combinations for the treatment of soft-tissue sarcoma: a review.Imatinib-refractory gastrointestinal stromal tumors: the clinical problem and therapeutic strategies.Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment.Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors.Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.
P50
Q27824804-9A7DDDB7-9090-47A0-A064-38F15E070FA1Q28485315-2FB078ED-FB9B-4537-9BC1-D9737696B1F2Q30425914-303C762B-5D11-4526-A604-A3E58241B520Q30429708-82720B52-590B-4C27-A0C2-09F5E4F88C0AQ33273478-A7CDBC64-2BEA-40B5-85F4-2E00C8DAB7A5Q33274815-6176A5A4-A489-4775-B51A-775F72E4F2D3Q33276227-575DA808-A466-4A85-AB2E-FC95ECEDF476Q33381641-A48A73AA-D1F0-4019-8F59-760D3AA960A0Q33385642-40CEB016-80B0-4F6D-8CE0-201864D6DF6DQ33442984-81DAB9AC-FAF4-4DF5-BD91-3CE1731ACF12Q33654894-3CAA1E0E-825C-4F90-9C18-C765B5B91A4DQ33676809-D11F4882-99FC-4FD4-8A9B-EA034533A980Q33695315-422D6049-8C7A-40C7-B3F1-70C0E4D415E2Q33710553-D242432A-EBE4-4660-B8BA-04B3FA043697Q33723424-9291F868-F4A4-445A-8DE4-908CEBAFBD78Q33802730-ADA5ABE3-9B36-455E-A6E1-CE0A78C84EADQ33817421-2EFC9CEB-C4F5-4BF9-9150-7CB1F77CECAFQ33916661-940C3224-1EF4-4150-ACAB-7FA48CC45E8AQ33921067-D160AA6F-F2E1-4964-BF2A-D74EA97220B7Q34041573-B001F979-126A-4EBC-B0DD-0A09CD79D588Q34202396-31898E00-ED42-413F-BF1B-2B9D17AC2B3DQ34289180-0053A124-C549-498D-8E01-32D1B850260DQ34359712-43F5E122-CA41-4E4A-A389-ED49534935C7Q34520595-BB79212C-11AD-4371-86DC-77CB8A85BF20Q34610473-90E93D0C-E8D6-45C7-B832-4D17D03BFBA0Q34641349-EEB1C340-E670-47F3-BCDE-72D0C8ED83ADQ34645665-6DF2956D-D934-48C3-AA95-0C134D27BEFCQ34661218-4048EFF5-68BE-4FFB-9B43-3DA2124CE22BQ34677531-73840D74-07C3-4491-B5FB-6C9B9F8D90B3Q35044199-0DAAD4E9-C300-4FA0-93CE-3E7A14F5CBA9Q35143939-47E1C7DE-B851-499F-B428-D61351B399DEQ35553853-DC03F5A2-03C9-455C-B5A8-2B5A149E52F5Q35571193-71302DFB-0033-439F-BCF9-B59CA016FC25Q35671104-2AB3F1B9-7CF5-4411-9BD3-14BDDE859198Q36052287-04C20C66-C54B-40E0-B72B-30DD6D778383Q36444369-CC592C0A-BBDA-40E6-A74C-BEDF77207969Q36450775-C1D56300-A1CA-4B62-976B-BD4DC3E358BAQ36455017-5BE1048F-1B5E-45C1-9CF1-02ABA03BB3EBQ36587153-36E3F2FA-5245-4546-9D21-B189C49B66BAQ36622330-5F939D99-1557-4379-BA1E-06D330EBBDFE
P50
name
Margaret von Mehren
@ast
Margaret von Mehren
@en
Margaret von Mehren
@nl
type
label
Margaret von Mehren
@ast
Margaret von Mehren
@en
Margaret von Mehren
@nl
prefLabel
Margaret von Mehren
@ast
Margaret von Mehren
@en
Margaret von Mehren
@nl